Lilin Lai

Lilin Lai

Auto-generated profile, based on publicly available information

Lilin Lai

Department of Pediatrics, Center for Childhood Infections and Vaccines, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2008 in Nature
Verified
Journal Article
Open access
PDF file
Vijayakumar VeluVijayakumar Velu
Vijayakumar Velu
KTKehmia Titanji
Kehmia Titanji
BZBaogong Zhu
Baogong Zhu
SHSajid Husain
Sajid Husain
APAnnette Pladevega
Annette Pladevega
RARama Rao Amara
Rama Rao Amara
Blockade of PD-1 (programmed death-1), a B7/CD28 family immune-receptor molecule that inhibits the immune response to chronic viral infections, is shown to improve anti-viral immune responses in SIV-infected macaques without adverse side effects. The treatment, which used an antibody specific to human PD-1, also prolonged survival. PD-1 blockade was effective without antiretroviral drugs, suggesting that a similar approach might also be effective in HIV/AIDS patients, combined perhaps with drugs or therapeutic vaccination. This study shows that blockade of PD-1 in SIV-infected macaques transiently increases the frequency, activation and functionality markers of virus-specific CD8 T cells without adverse side effects. Chronic immunodeficiency virus infections are characterized by dysfunctional cellular and humoral antiviral immune responses1,2,3. As such, immune modulatory therapies that enhance and/or restore the function of virus-specific immunity may protect from disease progression. Here we investigate the safety and immune restoration potential of blockade of the co-inhibitory receptor programmed death 1 (PD-1)4,5 during chronic simian immunodeficiency virus (SIV) infection in macaques. We demonstrate that PD-1 blockade using an antibody to PD-1 is well tolerated and results in rapid expansion of virus-specific CD8 T cells with improved functional quality. This enhanced T-cell immunity was seen in the blood and also in the gut, a major reservoir of SIV infection. PD-1 blockade also resulted in proliferation of memory B cells and increases in SIV envelope-specific antibody. These improved immune responses were associated with significant reductions in plasma viral load and also prolonged the survival of SIV-infected macaques. Blockade was effective during the early (week 10) as well as late (∼week 90) phases of chronic infection even under conditions of severe lymphopenia. These results demonstrate enhancement of both cellular and humoral immune responses during a pathogenic immunodeficiency virus infection by blocking a single inhibitory pathway and identify a novel therapeutic approach for control of human immunodeficiency virus infections.

1 August 2017 in The Lancet
Verified
Journal Article
Closed access
NRNadine Rouphael
Nadine Rouphael
MPMichele Paine
Michele Paine
RMRegina Mosley
Regina Mosley
SHSebastien Henry
Sebastien Henry
DMDevin V McAllister
Devin V McAllister
WNWendy Nesheim
Wendy Nesheim

1 January 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
Kristy MurrayKristy Murray
Kristy Murray
RGRodion Gorchakov
Rodion Gorchakov
ACAnna R. Carlson
Anna R. Carlson
RBRebecca Berry
Rebecca Berry
LLLilin Lai
Lilin Lai
MMMark J. Mulligan
Mark J. Mulligan
Infection with Zika virus is an emerging public health crisis. We observed prolonged detection of virus RNA in vaginal mucosal swab specimens and whole blood for a US traveler with acute Zika virus infection who had visited Honduras. These findings advance understanding of Zika virus infection and provide data for additional testing strategies.

1 March 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
PGPaul A. Goepfert
Paul A. Goepfert
MEMarnie L. Elizaga
Marnie L. Elizaga
ASAlicia Sato
Alicia Sato
LQLi Qin
Li Qin
MCMassimo Cardinali
Massimo Cardinali
TNthe National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network
the National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network
Background. Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming Methods. GeoVax pGA2/JS7 DNA (D) and MVA/HIV62 (M) vaccines encode noninfectious virus-like particles. Intramuscular needle injections were used to deliver placebo, 2 doses of DNA followed by 2 doses of rMVA (DDMM), one dose of DNA followed by 2 doses of rMVA (DMM), or 3 doses of rMVA (MMM) to HIV-seronegative participants. Results. Local and systemic symptoms were mild or moderate. Immune response rates for CD4 + and CD8 + T cells were highest in the DDMM group and lowest in the MMM group (77% vs 43% CD4 + and 42% vs 17% CD8 +). In contrast, response rates for Env binding and neutralizing Ab were highest in the MMM group. The DMM group had intermediate response rates. A 1/10th-dose DDMM regimen induced similar T cell but reduced Ab response rates compared with the full-dose DDMM. Conclusions. MVA62 was well tolerated and elicited different patterns of T cell and Ab responses when administered alone or in combination with the JS7 DNA vaccine.

15 October 2004 in Journal of Virology
Verified
Journal Article
Open access
PDF file
BTBrian A. Van Tine
Brian A. Van Tine
JKJohn C. Kappes
John C. Kappes
NBN. Sanjib Banerjee
N. Sanjib Banerjee
JKJudith Knops
Judith Knops
LLLilin Lai
Lilin Lai
LCLouise T. Chow
Louise T. Chow
Primary keratinocytes immortalized by human papillomaviruses (HPVs), along with HPV-induced cervical carcinoma cell lines, are excellent models for investigating neoplastic progression to cancer. By simultaneously visualizing viral DNA and nascent viral transcripts in interphase nuclei, we demonstrated for the first time a selection for a single dominant papillomavirus transcription center or domain (PVTD) independent of integrated viral DNA copy numbers or loci. The PVTD did not associate with several known subnuclear addresses but was almost always perinucleolar. Silent copies of the viral genome were activated by growth in the DNA methylation inhibitor 5-azacytidine. HPV-immortalized keratinocytes supertransduced with HPV oncogenes and selected for marker gene coexpression underwent crisis, and the surviving cells transcribed only the newly introduced genes. Thus, transcriptional selection in response to environmental changes is a dynamic process to achieve optimal gene expression for cell survival. This phenomenon may be critical in clonal selection during carcinogenesis. Examination of HPV-associated cancers supports this hypothesis.

13 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AEAli H. Ellebedy
Ali H. Ellebedy
RNRaffael Nachbagauer
Raffael Nachbagauer
KJKatherine J. L. Jackson
Katherine J. L. Jackson
YDYa-Nan Dai
Ya-Nan Dai
JHJulianna Han
Julianna Han
RARafi Ahmed
Rafi Ahmed
Significance: The development of a universal influenza vaccine is a major public health need globally, and identifying the optimal formulation will be an important first step for developing such a vaccine. Here we show that a two-dose immunization of humans with an inactivated, AS03-adjuvanted H5N1 avian influenza virus vaccine engaged both the preexisting memory and naive B cell compartments. Importantly, we show that the recruited memory B cells after first immunization were directed against conserved epitopes within the H5 HA stem region while the responses after the second immunization were mostly directed against strain-specific epitopes within the HA globular head. Taken together these findings have broad implications toward optimizing vaccination strategies for developing more effective vaccines against pandemic viruses.